OpenNashEarnings

Life Sciences · Nasdaq: ILMN

Illumina earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends January · next results expected around 4 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 FY2026

Illumina is pairing strong NovaSeq X placements and clinical sequencing demand with a push into AI-ready biology data via its Billion Cell Atlas, now over halfway complete.

Clinical sequencing demand and NovaSeq X placements drove the quarter, with over 80 instruments placed. Clinical consumables grew 14 % in the rest of the world, while research and applied consumables kept shrinking. Several of the largest clinical customers placed multi-unit capacity orders. Illumina also launched the BioInsight analysis platform with a new splicing AI model. GSK joined the Billion Cell Atlas Consortium, and interest in leases is rising among research and mid-size clinical labs.

Read the Q3 FY2026 summary →

Quarters

KPI history

Revenue$1.1B+4.2% y/yQ3 FY26
Q4 FY24: $1.1B (worked out from the annual figure)Q4 24$1.1BQ1 FY25: $1.0BQ1 25$1.0BQ2 FY25: $1.1BQ2 25$1.1BQ3 FY25: $1.1BQ3 25$1.1BQ4 FY25: $1.2B (worked out from the annual figure)Q4 25$1.2BQ1 FY26: $1.1BQ1 26$1.1BQ2 FY26: $1.2BQ2 26$1.2BQ3 FY26: $1.1BQ3 26$1.1B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$1.1B *
Q1 FY25$1.0B
Q2 FY25$1.1B
Q3 FY25$1.1B
Q4 FY25$1.2B *
Q1 FY26$1.1B
Q2 FY26$1.2B
Q3 FY26$1.1B
Diluted EPS (GAAP)$1.43+45.9% y/yQ3 FY26
Q1 FY25: $0.82Q1 25$0.82Q2 FY25: $1.49Q2 25$1.49Q3 FY25: $0.98Q3 25$0.98Q1 FY26: $0.87Q1 26$0.87Q2 FY26: $1.35Q2 26$1.35Q3 FY26: $1.43Q3 26$1.43
Data
Q1 FY25$0.82
Q2 FY25$1.49
Q3 FY25$0.98
Q1 FY26$0.87
Q2 FY26$1.35
Q3 FY26$1.43

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin27.0%+6.1 pts y/yQ3 FY26
Q4 FY24: 15.9%Q4 2415.9%Q1 FY25: 15.8%Q1 2515.8%Q2 FY25: 20.2%Q2 2520.2%Q3 FY25: 20.9%Q3 2520.9%Q4 FY25: 17.3%Q4 2517.3%Q1 FY26: 19.2%Q1 2619.2%Q2 FY26: 21.1%Q2 2621.1%Q3 FY26: 27.0%Q3 2627.0%
Data
Q4 FY2415.9%
Q1 FY2515.8%
Q2 FY2520.2%
Q3 FY2520.9%
Q4 FY2517.3%
Q1 FY2619.2%
Q2 FY2621.1%
Q3 FY2627.0%
Free cash flow$379.0M+49.8% y/yQ3 FY26
Q4 FY24: $335.0MQ4 24$335.0MQ1 FY25: $208.0MQ1 25$208.0MQ2 FY25: $204.0MQ2 25$204.0MQ3 FY25: $253.0MQ3 25$253.0MQ4 FY25: $266.0MQ4 25$266.0MQ1 FY26: $251.0MQ1 26$251.0MQ2 FY26: $161.0MQ2 26$161.0MQ3 FY26: $379.0MQ3 26$379.0M
Data
Q4 FY24$335.0M
Q1 FY25$208.0M
Q2 FY25$204.0M
Q3 FY25$253.0M
Q4 FY25$266.0M
Q1 FY26$251.0M
Q2 FY26$161.0M
Q3 FY26$379.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$1.1Bd$1.0B$1.1B$1.1B$1.2Bd$1.1B$1.2B$1.1B
Gross margin65.9%65.6%65.6%67.6%65.5%66.1%66.4%73.5%
Operating income$175.0Md$164.0M$214.0M$227.0M$201.0Md$209.0M$245.0M$305.0M
Operating margin15.9%15.8%20.2%20.9%17.3%19.2%21.1%27.0%
Net income$186.0M$131.0M$235.0M$150.0M$334.0M$134.0M$207.0M$220.0M
Diluted EPS—$0.82$1.49$0.98—$0.87$1.35$1.43
Operating cash flow$364.0Md$240.0M$234.0Md$284.0Md$321.0Md$289.0M$201.0Md$419.0Md
Capital expenditure$29.0Md$32.0M$30.0Md$31.0Md$55.0Md$38.0M$40.0Md$40.0Md
Free cash flow$335.0M$208.0M$204.0M$253.0M$266.0M$251.0M$161.0M$379.0M
R&D expense$256.0Md$252.0M$247.0M$229.0M$239.0Md$240.0M$252.0M$244.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings